Shanghai Medicilon Inc.

  Recently, Shanghai Medicilon Inc. (Medicilon) and SciMatchmaker reached a strategic collaboration.  The two parties have reached an agreement on collaboration in new drug research and development and resource sharing.  The joint advantages of the two sides complement each other.   Through continuous in-depth collaboration, they will open up new project potentials in new areas.  Through powerful system transformation services and proof-of-concept technologies to jointly promote the transformation from "science" to "technology", especially the industrialization of major basic research results, both parties will jointly assist in the verification, transformation, promotion and application of early scientific research results, and actively promote a deeply integrated technological innovation system. SciMatchmaker is committed to establish an all-ecological platform for the transfer and transformation of innovative medical scientific and technological achievements ...

  Medicilon-Preclinical CRO： Medicilon (stock code: 688202. SH) is a drug research and development outsourcing service company (CRO). Pharmacology, pharmacokinetics, and toxicology evaluation are comprehensive technical service platforms that meet international standards. Medicilon is one of the internationalized companies in China's local CRO. In 2008, it cooperated with MPI Research of the United States to establish an animal experiment company. The animal experiment facilities have obtained the International Laboratory Animal Assessment and Accreditation (AAALAC) and China Food and Drug Administration GLP certificates. We have reached the US Food and Drug Administration GLP standards. Medicilon will help customers achieve their goals faster with efficient and cost-effective one-stop professional services. CRO companies mainly provide pharmaceutical outsourcing services for pharmaceutical companies, pharmaceutical factories, schools, and other institutions. They started relativel...